Allscripts (NASDAQ:MDRX) has picked up a rare Sell rating in the U.S. Goldman Sachs analyst Robert Jones cut his rating and price target to $5.50 (from $6.50), implying 24% downside risk, citing its “unfavorable” position in the healthcare IT space and doubts about its growth prospects.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.